Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.58 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.44 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.44 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.44 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.44 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29854659 | 1.00 | P4HTM (0.58) | P4HTMDAOFFAR1FFAR4CA1 | |
| SCHEMBL3938190 | 0.90 | PLAAT3 (0.50) | P4HTMDAOFFAR1PLAAT3PLAAT5 | |
| SCHEMBL30426996 | 0.90 | PLAAT3 (0.50) | P4HTMDAOFFAR1PLAAT3PLAAT5 | |
| SCHEMBL27654168 | 0.85 | DAO (0.48) | P4HTMDAOPLAAT3PLAAT5PLAAT2 | |
| SCHEMBL15087614 | 0.85 | DAO (0.48) | P4HTMDAOPLAAT3PLAAT5PLAAT2 | |
| SCHEMBL15215450 | 0.83 | P4HTM (0.58) | P4HTMFFAR1FFAR4CA1CA2 | |
| SCHEMBL30025563 | 0.83 | GABRP (0.56) | P4HTMDAOCA2PLAAT3PLAAT5 | |
| SCHEMBL263863 | 0.83 | GABRP (0.56) | P4HTMDAOCA2PLAAT3PLAAT5 | |
| SCHEMBL12457131 | 0.81 | DAO (0.45) | P4HTMDAOPLAAT3PLAAT5PLAAT2 | |
| SCHEMBL2949235 | 0.81 | DAO (0.45) | DAOPLAAT3PLAAT5PLAAT2PLAAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118239953-A | Compounds for the treatment of PI3K gamma mediated diseases and uses thereof | 中国科学院合肥物质科学研究院 | 2024-06-25 | — | — | CN | disclosed |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
| CN-116789670-A | Selective CSF1R inhibitor and application thereof | 中国科学院合肥物质科学研究院 | 2023-09-22 | — | — | CN | disclosed |
| WO-2023173480-A1 | SELECTIVE CSF1R INHIBITOR AND USE THEREOF | 中国科学院合肥物质科学研究院 | 2023-09-21 | — | — | WO | disclosed |
| WO-2023287964-A1 | LIGAND-CONTROLLED DIVERGENT DEHYDROGENATIVE REACTIONS OF ALIPHATIC ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20210186963-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-06-24 | — | — | US | disclosed |
| US-10980806-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-04-20 | — | — | US | disclosed |
| EP-2900669-B1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | disclosed |
| EP-3433239-A1 | SMALL MOLECULE INHIBITOR OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | University of Pittsburgh- Of the Commonwealth System of Higher Education (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20190022093-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-01-24 | — | — | US | disclosed |
| US-20070191424-A1 | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2007-08-16 | — | — | US | disclosed |
| US-20070191424-A1 | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2007-08-16 | — | — | US | disclosed |
| CN-1926109-A | Substituted 1,2,3, 4-tetrahydroisoquinoline derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2007-03-07 | — | — | CN | disclosed |
| EP-1751111-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2007-02-14 | — | — | EP | disclosed |
| CN-1835950-A | Imidazopyridine derivatives | BANYU PHARMA CO LTD (JP) | 2006-09-20 | — | — | CN | disclosed |
| US-7084156-B2 | 2-Aminoquinoline compounds | MERCK & CO., INC. (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1657242-A1 | IMIDAZOPYRIDINE DERIVATIVES | Banyu Pharmaceutical Co., Ltd. (JP) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005118548-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005118548-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2005-12-15 | — | — | WO | disclosed |
| US-20050026915-A1 | 2-Aminoquinoline compounds | MERCK SHARP & DOHME CORP. | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186963-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | AR, NR0B1, NCOA3 | P4HTM 1817/4885DAO 512/4885FFAR1 323/4885 |
| US-20190022093-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | AR, NR0B1, NCOA3 | P4HTM 1846/4885DAO 515/4885FFAR1 300/4885 |
| US-20070191424-A1 | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives | CPT1A, NQO1, COQ8A | P4HTM 2419/4885DAO 4492/4885FFAR1 2495/4885 |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | AR, NR0B1, NCOA3 | P4HTM 1839/4885DAO 528/4885FFAR1 306/4885 |
| US-10980806-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | AR, NR0B1, NCOA3 | P4HTM 1839/4885DAO 528/4885FFAR1 306/4885 |
| US-20050026915-A1 | 2-Aminoquinoline compounds | MCHR1, MCHR2, MC5R | P4HTM 1487/4885DAO 874/4885FFAR1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.